This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Clovis Smart Move is to Drop Damaged Lung Cancer Drug Altogether

Clovis Oncology is better off if the U.S. Food and Drug Administration rejects its lung cancer drug rociletinib.

Relypsa Fielding Takeout Offers, Shares Move Higher

Relypsa has hired an investment bank and is exploring a sale following the receipt of offers from a "number of potential buyers," Reuters reports.

Biotech M&A Will Flow From the Ashes of Scuttled Pfizer-Allergan Merger

Both Allergan and Pfizer could target biotech and drug company acquisitions as a way to fuel future growth.

This Drug Company Loaned Its Now-Fired CEO $2.5M for Made-Up Travel 'Advances'

The extravagant travel-expense payouts to Provectus CEO Craig leaves the company at risk of criminal or civil investigations by the Securities and Exchange Commission.

Reasons for Vertex's Stock Slump Since Last Summer Center on Orkambi Launch

Vertex's stock price has been cut almost in half since the cystic fibrosis drug Orkambi launched last summer.

Gilead Bolsters Liver Disease Pipeline with Nimbus Drug Purchase

Central to the Gilead purchase is a Nimbus compound with a novel mechanism of action targeting nonalcoholic steatohepatitis (NASH), better known as fatty liver disease.

AB Science Claims ALS Drug Success in Opaque Trial Announcement

Incomplete information from the AB Science trial makes it difficult to ascertain if ALS patient truly benefited from the company's lead compound masitinib.

Biotech Stock Mailbag: Intercept, Acadia, Keryx, Galena

TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stock investing.

Amicus Fabry Drug Takes Big Step Toward European Approval

A committee of European drug reviewers voted Friday to recommend the approval of the first oral treatment for Fabry disease, developed by Amicus Therapeutics.

Acadia Pharma FDA Advisory Panel Live Blog

A panel of outside experts selected by the FDA are reviewing a Parkinson's disease drug developed by Acadia Pharmaceuticals.

Page 3 of 357
Top Rated Stocks Top Rated Funds Top Rated ETFs